Skip to content
OpenCapital
Get started

Viking Therapeutics VKTX Q3 2025 earnings

Reported October 22, 2025 · After market close

Revenue-
EPS-$0.81Miss by $0.11
EPS estimate-$0.70

Next report

Oct 28, 2026 (in 3 months)
EPS estimate-$1.11

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$98.6M-170%
Net income-$90.8M-264%
EPS (diluted)-$0.81-268%

Balance sheet

See full
Cash & equivalents$100.4M+99.4%
Total debt$755.0K-38.9%
Total equity$713.0M-21.8%
Total assets$739.4M-21.2%

Cash flow

See full
Operating cash flow-$94.0M-328%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.96B-57.7%
Enterprise value$2.86B-58.9%

Returns & leverage

See full
Return on equity-29.2%+227pp
Debt / equity0×0.0×
Current ratio28.3×-8.1×

Versus estimates

Diluted EPS

Q2 2026-$1.10Beat by $0.11Q1 2026-$1.37Miss by $0.36Q4 2025-$1.38Miss by $0.49
Q3 2025-$0.81Miss by $0.11
Q2 2025-$0.58Miss by $0.14Q1 2025-$0.41Miss by $0.07

Ask the moment Viking Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Viking Therapeutics report Q3 2025 earnings?
Viking Therapeutics (VKTX) reported Q3 2025 earnings on October 22, 2025 after market close.
What were Viking Therapeutics's Q3 2025 revenue and EPS?
Viking Therapeutics reported revenue of - and eps of $-0.81 for Q3 2025.
Did Viking Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.70 by $0.11.
How did Viking Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 268.2% from $-0.22.
Where can I find Viking Therapeutics's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001193125-25-247059) directly on SEC EDGAR. The filing index links above go to sec.gov.